These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27723882)

  • 21. Prolactinoma in a Dog.
    Cosio C; Sartori E; Garatti M; Luccardini L; Grinwis GCM; Kooistra HS; Fracassi F
    Vet Pathol; 2017 Nov; 54(6):972-976. PubMed ID: 28812531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?
    Karavitaki N; Dobrescu R; Byrne JV; Grossman AB; Wass JA
    Clin Endocrinol (Oxf); 2013 Aug; 79(2):217-23. PubMed ID: 23215960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy.
    Bronstein MD
    Nat Clin Pract Endocrinol Metab; 2006 Mar; 2(3):130-1. PubMed ID: 16932269
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas.
    Bhansali A; Walia R; Dutta P; Khandelwal N; Sialy R; Bhadada S
    Indian J Med Res; 2010 Apr; 131():530-5. PubMed ID: 20424304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Late-onset hypogonadism: a concept comes of age.
    Nieschlag E
    Andrology; 2020 Nov; 8(6):1506-1511. PubMed ID: 31639279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluaton of therapy with cabergoline in men with macroprolactinoa.
    Andrysiak-Mamos E; Kaźmierczyk-Puchalska A; Zochowska E; Sowińska-Przepiera E; Sagan L; Kojder I; Syrenicz A
    Pomeranian J Life Sci; 2015; 61(3):263-9. PubMed ID: 27344867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cabergoline treatment of pregnant women with macroprolactinomas.
    Laloi-Michelin M; Ciraru-Vigneron N; Meas T
    Int J Gynaecol Obstet; 2007 Oct; 99(1):61-2. PubMed ID: 17602689
    [No Abstract]   [Full Text] [Related]  

  • 29. [Efficacy of cabergoline in the treatment of macroprolactinoma].
    Dupuy O; Le Marec E; Mayaudon H; Rilminger H; Bordier L; Bauduceau B
    Presse Med; 2003 Jan; 32(2):71-2. PubMed ID: 12653031
    [No Abstract]   [Full Text] [Related]  

  • 30. Concomitant Cushing's Disease and Marked Hyperprolactinemia: Response to a Dopamine Receptor Agonist.
    Shiraishi J; Koyama H; Shirakawa M; Ishikura R; Okazaki H; Kurajoh M; Shoji T; Moriwaki Y; Yamamoto T; Namba M
    Intern Med; 2016; 55(8):935-41. PubMed ID: 27086808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
    Laboy-Ortiz IE; Velez-Maymí S; Hernán Martínez J; Trinidad R; Mangual M; Sanchez A; Gutierrez M; Mansilla P; Rivera C; Palermo C; de Lourdes Miranda M; Brau R
    Bol Asoc Med P R; 2016; 108(1):31-36. PubMed ID: 29193928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.
    Cackett P; Eunson G; Bath L; Mulvihill A
    Future Oncol; 2012 Dec; 8(12):1621-6. PubMed ID: 23231524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature.
    Berwaerts J; Verhelst J; Abs R; Appel B; Mahler C
    J Endocrinol Invest; 2000 Jun; 23(6):393-8. PubMed ID: 10908167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Critical evaluation of different available guidelines for late-onset hypogonadism.
    Giagulli VA; Castellana M; Lisco G; Triggiani V
    Andrology; 2020 Nov; 8(6):1628-1641. PubMed ID: 32593233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.
    Colao A; Lombardi G
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2756. PubMed ID: 9253368
    [No Abstract]   [Full Text] [Related]  

  • 36. Pneumocephalus during cabergoline treatment of an invasive macroprolactinoma.
    Jouret F; Col V
    Acta Clin Belg; 2009; 64(5):457. PubMed ID: 19999399
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of the dopamine agonist cabergoline on the pulsatile and TRH-induced secretion of prolactin, LH, and testosterone in male beagle dogs.
    Koch A; Hoppen HO; Dieleman SJ; Kooistra HS; Günzel-Apel AR
    Theriogenology; 2006 May; 65(8):1666-77. PubMed ID: 16289263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pituitary apoplexy associated with cabergoline therapy.
    Chng E; Dalan R
    J Clin Neurosci; 2013 Dec; 20(12):1637-43. PubMed ID: 24113159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testosterone and benign prostatic hyperplasia.
    Jarvis TR; Chughtai B; Kaplan SA
    Asian J Androl; 2015; 17(2):212-6. PubMed ID: 25337845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnosis and management of testosterone deficiency.
    McBride JA; Carson CC; Coward RM
    Asian J Androl; 2015; 17(2):177-86. PubMed ID: 25532575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.